| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/03/2013 | CA2504963C Conjugates of tnf and a ligand of cd13 receptor in combination with interferon-gamma for treating cancer |
| 09/03/2013 | CA2483330C Multimeric ligands with enhanced stability |
| 09/03/2013 | CA2478294C Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants |
| 09/03/2013 | CA2464372C Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof |
| 09/03/2013 | CA2459807C Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 09/03/2013 | CA2428798C Fen-1 endonucleases from archaeoglobus veneficus |
| 09/03/2013 | CA2421865C Olfactory and pheromones g-protein coupled receptors |
| 09/03/2013 | CA2412581C Transforming growth factor beta (tgf-.beta.) blocking agent-treated stem cell composition and method |
| 09/03/2013 | CA2398277C The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity |
| 09/03/2013 | CA2245877C Hybrid proteins which form heterodimers |
| 09/03/2013 | CA2241564C Wsx receptor and ligands |
| 08/29/2013 | WO2013126919A1 Nemo binding domain fusion proteins |
| 08/29/2013 | WO2013126872A1 Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients |
| 08/29/2013 | WO2013126794A1 Compositions and methods for the treatment of hemoglobinopathies |
| 08/29/2013 | WO2013126776A1 Nanostructures for treating cancers and other conditions |
| 08/29/2013 | WO2013126775A1 Aromatic-cationic peptides and uses of same |
| 08/29/2013 | WO2013126703A1 Reversibly crosslinked helical hydrogen bond surrogate macrocycles |
| 08/29/2013 | WO2013126597A1 Methods and compositions for preventing or treating ophthalmic conditions |
| 08/29/2013 | WO2013126587A1 Systems, compositions, and methods for transplantation |
| 08/29/2013 | WO2013126581A1 Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| 08/29/2013 | WO2013126402A1 Composition and methods for treating melanoma |
| 08/29/2013 | WO2013126017A1 Organogels and emulsions for biological and non-biological applications |
| 08/29/2013 | WO2013126006A1 Polypeptides binding to human complement c5 |
| 08/29/2013 | WO2013124855A1 Hydrogel system comprising spatially separated bioactive polypeptides |
| 08/29/2013 | WO2013124668A1 Use of igbpma for binding iga |
| 08/29/2013 | WO2013124620A1 Method of making a hydrogel |
| 08/29/2013 | WO2013124484A1 Compositions and methods for the treatment of retinal degeneration |
| 08/29/2013 | WO2013124477A1 Methods and compositions for treatment of retinal degenerative diseases |
| 08/29/2013 | WO2013124463A1 Relaxin for treating patients afflicted of impaired glucose tolerance |
| 08/29/2013 | WO2013124436A1 Synthetic anti-microbial peptides with a minority of cationic and a majority hydrophobic side chains |
| 08/29/2013 | WO2013124416A1 Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
| 08/29/2013 | WO2013102144A8 Ph20 polypeptide variants, formulations and uses thereof |
| 08/29/2013 | WO2013098755A3 Anticancer fusion protein |
| 08/29/2013 | WO2008004717A9 A stable liquid formulation of human growth hormone |
| 08/29/2013 | US20130225510 Methods for the use of branched chain amino acids |
| 08/29/2013 | US20130225509 Method to enhance endurance |
| 08/29/2013 | US20130225503 Tex14 peptides as novel antitumor agents |
| 08/29/2013 | US20130225502 Combination therapy with w t 1 peptide vaccine and temozolomide |
| 08/29/2013 | US20130225501 Skin collagen production-promoting agent |
| 08/29/2013 | US20130225499 Method for administering omega-conopeptide |
| 08/29/2013 | US20130225498 Composition for preventing or treating neurodegenerative diseases containing ccl5 |
| 08/29/2013 | US20130225495 Formulations having an antagonist of alpha 5 beta 1 for anti-angiogenesis and cancer treatment |
| 08/29/2013 | US20130225494 Formulations having an alpha v beta 3 antagonist and an alpha 2 beta 1 antagonist for anti-angionic therapy |
| 08/29/2013 | US20130225493 FGF-18 Truncated Variants Having Increased Receptor Specificity And Uses Thereof |
| 08/29/2013 | US20130225492 Sustained-Release Pharmaceutical Composition |
| 08/29/2013 | US20130225491 Methods and Kits for Treating Disease By Administering Insulin-Like Growth Factor Binding Protein-2 |
| 08/29/2013 | US20130225490 Antibodies That Inhibit TSLP Activity |
| 08/29/2013 | US20130225489 Methods for administering hypoglycemic agents |
| 08/29/2013 | US20130225485 Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders |
| 08/29/2013 | US20130225483 New Treatments of Hepatitis C Virus Infection |
| 08/29/2013 | US20130225480 Method of Treating Chronic Obstructive Pulmonary Disease |
| 08/29/2013 | US20130225479 Methods and Compositions for Treating Inflammation |
| 08/29/2013 | US20130225477 Oral Lactoferrin in the Treatment of Severe Sepsis |
| 08/29/2013 | US20130225412 Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment |
| 08/29/2013 | US20130224834 Anti-androgenic agent, sebum secretion blocker, hair growth stimulant, and food or beverage |
| 08/29/2013 | US20130224769 Methods of using chemokine panec-1 antibodies |
| 08/29/2013 | US20130224766 Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| 08/29/2013 | US20130224313 Cancer therapy method |
| 08/29/2013 | US20130224283 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
| 08/29/2013 | US20130224280 Transdermal compositions and methods for treating stretch marks |
| 08/29/2013 | US20130224255 Treatment Of Diabetic Patients With A Drug Eluting Stent And Adjunctive Therapy |
| 08/29/2013 | US20130224243 Use of herpes vectors for tumor therapy |
| 08/29/2013 | US20130224227 Novel conjugates of cc-1065 analogs and bifunctional linkers |
| 08/29/2013 | US20130224223 Compositions and Methods for Treating Neurological Disorders |
| 08/29/2013 | US20130224218 Methods and Compositions for the Inhibition of Fructokinase |
| 08/29/2013 | US20130224189 Tweak receptor |
| 08/29/2013 | US20130224185 Protein formulation |
| 08/29/2013 | US20130224180 Injection paradigm for administration of botulinum toxins |
| 08/29/2013 | US20130224178 Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopepidases |
| 08/29/2013 | US20130224177 Method of regulating fertilizing ability using cyclic adp-ribose and cd38 |
| 08/29/2013 | US20130224176 Method of restoring the incretin effect |
| 08/29/2013 | US20130224172 Methods of treating behavioral symptoms of neurological and mental disorders |
| 08/29/2013 | US20130224171 Agent for use in the case of fructose intolerance |
| 08/29/2013 | US20130224164 Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use |
| 08/29/2013 | US20130224163 Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| 08/29/2013 | US20130224161 Methods for organ regeneration |
| 08/29/2013 | US20130224157 Stem cells for treating lung diseases |
| 08/29/2013 | US20130224149 Process for preparing antiviral compounds |
| 08/29/2013 | US20130224148 Activated leukocyte conditioned supernatant and uses for wound healing |
| 08/29/2013 | US20130224147 Macrocyclic serine protease inhibitors |
| 08/29/2013 | US20130224146 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling |
| 08/29/2013 | US20130224144 Sequential administration of a replication defective adenovirus vector in vaccination protocols |
| 08/29/2013 | US20130224118 Perhexiline for treating chronic heart failure |
| 08/29/2013 | DE112011103715T5 Herstellungsverfahren für Caspofungin Production methods for caspofungin |
| 08/28/2013 | EP2631244A1 Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them |
| 08/28/2013 | EP2631242A2 A process for concentration of a polypeptide |
| 08/28/2013 | EP2630972A2 N-terminal polysialylation |
| 08/28/2013 | EP2630965A1 A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS) |
| 08/28/2013 | EP2630964A1 Method and medicament for treating patients in risk of prediabetes and type-2 diabetes |
| 08/28/2013 | EP2630963A1 SPARC angiogenic domain and methods of use |
| 08/28/2013 | EP2630962A1 Low Frequency Glatiramer Acetate Therapy |
| 08/28/2013 | EP2630959A1 Treatment of inflammatory diseases using placental stem cells |
| 08/28/2013 | EP2630874A1 Methods for the use of branched chain amino acids |
| 08/28/2013 | EP2630238A1 Wdhd1 peptides and vaccines including the same |
| 08/28/2013 | EP2630237A1 C18orf54 peptides and vaccines including the same |
| 08/28/2013 | EP2630158A2 Discovery of regulatory t cells programmed to suppress an immune response |
| 08/28/2013 | EP2630154A1 Methods and compositions for modulating the wnt pathway |
| 08/28/2013 | EP2629790A1 Method to increase the growth velocity of human infants |
| 08/28/2013 | EP2629789A1 Method to increase the absorption of unsaturated fatty acids by human infants |
| 08/28/2013 | EP2629788A2 Use of human serum albumin to decrease antigenicity of therapeutic proteins |